Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RVNC
FechaHoraFuenteTítuloSímboloCompañía
17/01/202507:15Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
16/01/202504:45PR Newswire (US)Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCNASDAQ:RVNCRevance Therapeutics Inc
13/01/202507:44Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
13/01/202507:30PR Newswire (US)Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.NASDAQ:RVNCRevance Therapeutics Inc
13/01/202504:45PR Newswire (US)Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:RVNCRevance Therapeutics Inc
10/01/202515:52Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RVNCRevance Therapeutics Inc
09/01/202504:45PR Newswire (US)The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNCNASDAQ:RVNCRevance Therapeutics Inc
06/01/202508:00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
06/01/202508:00PR Newswire (US)Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in CashNASDAQ:RVNCRevance Therapeutics Inc
12/12/202407:01Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:RVNCRevance Therapeutics Inc
12/12/202407:00PR Newswire (US)Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per shareNASDAQ:RVNCRevance Therapeutics Inc
12/12/202406:15Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:RVNCRevance Therapeutics Inc
12/12/202405:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
09/12/202416:16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:RVNCRevance Therapeutics Inc
09/12/202408:24Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:RVNCRevance Therapeutics Inc
09/12/202407:30PR Newswire (US)Crown Laboratories and Revance Enter into Amended and Restated Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
19/11/202415:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
07/11/202415:05Business WireRevance Reports Third Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
27/09/202408:17PR Newswire (US)Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law FirmNASDAQ:RVNCRevance Therapeutics Inc
16/09/202416:01Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RVNCRevance Therapeutics Inc
12/08/202414:18PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.NASDAQ:RVNCRevance Therapeutics Inc
12/08/202407:00PR Newswire (US)Crown Laboratories and Revance Announce Entry Into Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
08/08/202415:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVNCRevance Therapeutics Inc
08/08/202415:05Business WireRevance Reports Second Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
01/08/202415:05Business WireRevance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:RVNCRevance Therapeutics Inc
14/06/202415:05Business WireRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RVNCRevance Therapeutics Inc
28/05/202415:05Business WireRevance to Participate in Upcoming Investor ConferencesNASDAQ:RVNCRevance Therapeutics Inc
09/05/202415:06Business WireRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
09/05/202415:05Business WireRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
02/05/202415:05Business WireRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC

Su Consulta Reciente

Delayed Upgrade Clock